Table 3.
Serological and inflammatory markers and their association with overall survival.
| Patients (%) | HR (95% CI) | p Value | |
|---|---|---|---|
| SEROLOGICAL MARKERS | |||
| CRP | |||
| Normal (<3) | 140 (54.5) | 1.00 | |
| High (≥3) | 113 (44.0) | 1.60 (0.94–2.71) | 0.08 |
| Albumin | |||
| Low (<35) | 12 (4.7) | 1.87 (0.68–5.19) | 0.23 |
| Normal (≥35) | 145 (56.4) | 1.00 | |
| Hemoglobin | |||
| Low (<13) | 88 (34.2) | 1.97 (1.17–3.34) | 0.01 |
| Normal (≥13) | 169 (65.8) | 1.00 | |
| Platelets | |||
| Normal (<390) | 243 (94.6) | 1.00 | |
| High (≥390) | 14 (5.4) | 2.19 (0.87–5.51) | 0.09 |
| Leucocytes | |||
| Normal (<11) | 231 (89.9) | 1.00 | |
| High (≥11) | 26 (10.1) | 1.17 (0.50–2.73) | 0.72 |
| Lymphocytes | |||
| Normal (<3.8) | 249 (96.9) | 1.00 | |
| High (≥3.8) | 8 (3.1) | 0.58 (0.08–4.16) | 0.58 |
| Neutrophils | |||
| Normal (<6.8) | 219 (85.2) | 1.00 | |
| High (≥6.8) | 38 (14.8) | 1.57 (0.81–3.04) | 0.18 |
| INFLAMMATORY MARKERS | |||
| HALP | |||
| <32.2 | 66 (25.7) | 2.78 (1.64–4.72) | 0.0002 |
| ≥32.2 | 91 (35.4) | 1.00 | |
| NLR | |||
| <2.29 | 101 (39.3) | 1.00 | |
| ≥2.29 | 156 (60.7) | 2.14 (1.17–3.93) | 0.01 |
| PLR | |||
| <196.1 | 209 (81.3) | 1.00 | |
| ≥196.1 | 48 (18.7) | 2.27 (1.28–4.02) | 0.005 |
| SII | |||
| <808.9 | 175 (68.1) | 1.00 | |
| ≥808.9 | 82 (31.9) | 2.59 (1.53–4.38) | 0.0004 |
| ALI | |||
| <34.86 | 85 (33.1) | 2.55 (1.51–4.31) | 0.0005 |
| ≥34.86 | 172 (66.9) | 1.00 | |
Data for CRP are missing for 4 patients. CRP: c-reactive protein; HALP: hemoglobin, albumin, lymphocyte, and platelet score; NLR: derived neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; SII: systemic immune-inflammation index; AL:, advanced lung cancer inflammation index. Cut-off values for serological markers are based on normal ranges, while those for inflammatory markers were obtained by receiver operating characteristic (ROC) curve analysis.